What the Hel: recent advances in understanding rifampicin resistance in bacteria

FEMS Microbiol Rev. 2023 Nov 1;47(6):fuac051. doi: 10.1093/femsre/fuac051.

Abstract

Rifampicin is a clinically important antibiotic that binds to, and blocks the DNA/RNA channel of bacterial RNA polymerase (RNAP). Stalled, nonfunctional RNAPs can be removed from DNA by HelD proteins; this is important for maintenance of genome integrity. Recently, it was reported that HelD proteins from high G+C Actinobacteria, called HelR, are able to dissociate rifampicin-stalled RNAPs from DNA and provide rifampicin resistance. This is achieved by the ability of HelR proteins to dissociate rifampicin from RNAP. The HelR-mediated mechanism of rifampicin resistance is discussed here, and the roles of HelD/HelR in the transcriptional cycle are outlined. Moreover, the possibility that the structurally similar HelD proteins from low G+C Firmicutes may be also involved in rifampicin resistance is explored. Finally, the discovery of the involvement of HelR in rifampicin resistance provides a blueprint for analogous studies to reveal novel mechanisms of bacterial antibiotic resistance.

Keywords: HelD/HelR; RNA polymerase; antibiotics; bacteria; resistance; rifampicin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteria* / genetics
  • Bacteria* / metabolism
  • DNA
  • DNA-Directed RNA Polymerases / genetics
  • DNA-Directed RNA Polymerases / metabolism
  • Drug Resistance, Bacterial
  • Rifampin* / pharmacology

Substances

  • Rifampin
  • DNA-Directed RNA Polymerases
  • Anti-Bacterial Agents
  • DNA